HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Parenteral gold therapy in the Felty syndrome. Experience with 20 patients.

Abstract
Most of the patients with the Felty syndrome suffer from such complications as fevers, infections, cutaneous ulcers, and vasculitis. Unfortunately, there are no therapeutic interventions that are predictably beneficial. We report our experience with 20 patients who received parenteral gold therapy for 2 to 114 months (mean, 23.6 months). All had complications of the Felty syndrome. On parenteral gold therapy, 60% had a complete response, 20% had a partial response, and 20% were unresponsive by preselected criteria. No serious complications were encountered. We think that parenteral gold therapy should be considered early, before other agents, in the treatment of this condition.
AuthorsA M Dillon, H S Luthra, D L Conn, R H Ferguson
JournalMedicine (Medicine (Baltimore)) Vol. 65 Issue 2 Pg. 107-12 (Mar 1986) ISSN: 0025-7974 [Print] United States
PMID3951357 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Gold
  • Rheumatoid Factor
Topics
  • Adult
  • Aged
  • Arthritis, Rheumatoid (drug therapy, immunology, physiopathology)
  • Felty Syndrome (blood, drug therapy, physiopathology)
  • Gold (administration & dosage, adverse effects, therapeutic use)
  • Humans
  • Injections, Intramuscular
  • Leukocyte Count
  • Middle Aged
  • Rheumatoid Factor (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: